Gaucher gene therapy FLT201 shows sustained clinical benefits
Treatment with the experimental gene therapy FLT201 led to sustained clinical benefits that lasted up to 21 months for people with Gaucher disease type 1, according to new clinical trial data. Spur Therapeutics, the therapy’s developer, presented the findings at the 28th annual meeting of the…